Prevents nausea and vomiting. ANDA 77535, held by Glenmark Pharms Ltd. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77535 (Ondansetron Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Jun 25, 2007, with 11 approved supplements and 0 published complete response letters.
Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2007 | Original application | Approved | None posted |
| Ondansetron HydrochlorideEQ 4MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Ondansetron HydrochlorideEQ 8MG BASE · tablet;oral | Ondansetron Hydrochloride | Rx |
| Ondansetron HydrochlorideEQ 24MG BASE · tablet;oral | Ondansetron Hydrochloride | Discontinued |
| Sep 9, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Feb 13, 2018 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 30, 2017 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 30, 2011 | Supplement 8Labeling | Approved | None posted |
| Sep 30, 2011 | Supplement 9Labeling | Approved | None posted |
| Jul 25, 2011 | Supplement 7Labeling | Approved | None posted |
| Oct 23, 2008 | Supplement 5Labeling | Approved | None posted |
| Aug 18, 2008 | Supplement 2Labeling | Approved | None posted |
| Aug 18, 2008 | Supplement 4Labeling | Approved | None posted |
| Jun 25, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters